nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Tamoxifen—pancreatic cancer	0.0363	0.24	CbGbCtD
Maraviroc—CYP3A4—Erlotinib—pancreatic cancer	0.0309	0.204	CbGbCtD
Maraviroc—CYP3A4—Irinotecan—pancreatic cancer	0.0279	0.185	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—pancreatic cancer	0.0204	0.135	CbGbCtD
Maraviroc—CYP3A4—Sunitinib—pancreatic cancer	0.0203	0.135	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—pancreatic cancer	0.0152	0.101	CbGbCtD
Maraviroc—CCR5—Peptide GPCRs—CCKAR—pancreatic cancer	0.00663	0.0212	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.00552	0.0177	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.00469	0.015	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.0045	0.0144	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—AGTR1—pancreatic cancer	0.00446	0.0143	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.00441	0.0141	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.00433	0.0139	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.00432	0.0138	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.00418	0.0134	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—CNR1—pancreatic cancer	0.0041	0.0131	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SSTR3—pancreatic cancer	0.00396	0.0127	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SSTR1—pancreatic cancer	0.00379	0.0121	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—PPY—pancreatic cancer	0.00372	0.0119	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.0037	0.0118	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.00367	0.0118	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SSTR2—pancreatic cancer	0.00365	0.0117	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.00352	0.0113	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.00339	0.0108	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.00327	0.0105	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.00325	0.0104	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00315	0.0101	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.00312	0.00998	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00302	0.00966	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00296	0.00947	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.0029	0.00929	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PRLHR—pancreatic cancer	0.00282	0.00902	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.0028	0.00898	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CNR2—pancreatic cancer	0.00267	0.00856	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL8—pancreatic cancer	0.00255	0.00817	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.00248	0.00794	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SST—pancreatic cancer	0.00246	0.00789	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—NFKBIA—pancreatic cancer	0.00245	0.00783	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00244	0.00781	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SSTR3—pancreatic cancer	0.0024	0.00767	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SSTR1—pancreatic cancer	0.0023	0.00735	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PPY—pancreatic cancer	0.00225	0.00721	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SSTR2—pancreatic cancer	0.00221	0.00708	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00218	0.00698	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCKBR—pancreatic cancer	0.00214	0.00684	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00213	0.0068	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR1—pancreatic cancer	0.0021	0.00671	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00209	0.00669	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SST—pancreatic cancer	0.00208	0.00665	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—pancreatic cancer	0.00194	0.00621	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CNR1—pancreatic cancer	0.00192	0.00614	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.00178	0.0057	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SCT—pancreatic cancer	0.00174	0.00557	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCK—pancreatic cancer	0.00166	0.00532	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00165	0.00529	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.00164	0.00525	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CNR2—pancreatic cancer	0.00162	0.00518	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—GLP1R—pancreatic cancer	0.00162	0.00518	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCKAR—pancreatic cancer	0.00159	0.0051	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00153	0.00488	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SHH—pancreatic cancer	0.00145	0.00465	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PRLHR—pancreatic cancer	0.00145	0.00463	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—IAPP—pancreatic cancer	0.00143	0.00459	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00141	0.0045	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTHLH—pancreatic cancer	0.00138	0.0044	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTCH1—pancreatic cancer	0.00138	0.0044	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00135	0.00433	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GDI1—pancreatic cancer	0.00133	0.00424	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GDI2—pancreatic cancer	0.00133	0.00424	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—pancreatic cancer	0.0013	0.00416	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—SSTR1—pancreatic cancer	0.0013	0.00416	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PPY—pancreatic cancer	0.00127	0.00407	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SST—pancreatic cancer	0.00126	0.00403	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00125	0.004	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SSTR3—pancreatic cancer	0.00123	0.00394	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00121	0.00386	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SSTR1—pancreatic cancer	0.00118	0.00377	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CNR1—pancreatic cancer	0.00116	0.00372	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PPY—pancreatic cancer	0.00116	0.0037	CbGpPWpGaD
Maraviroc—CCR5—Disease—ZNRF3—pancreatic cancer	0.00115	0.00367	CbGpPWpGaD
Maraviroc—CCR5—Disease—PRSS1—pancreatic cancer	0.00115	0.00367	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SSTR2—pancreatic cancer	0.00113	0.00363	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—GCG—pancreatic cancer	0.00112	0.00359	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCKBR—pancreatic cancer	0.0011	0.00351	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—AGTR1—pancreatic cancer	0.00107	0.00343	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GAST—pancreatic cancer	0.00104	0.00332	CbGpPWpGaD
Maraviroc—CCR5—Disease—DTX1—pancreatic cancer	0.00104	0.00332	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—pancreatic cancer	0.00102	0.00328	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—SCT—pancreatic cancer	0.000984	0.00315	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.00096	0.00307	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GAST—pancreatic cancer	0.000943	0.00302	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCK—pancreatic cancer	0.000939	0.003	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CNR2—pancreatic cancer	0.000915	0.00293	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000915	0.00293	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—pancreatic cancer	0.000905	0.0029	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCKAR—pancreatic cancer	0.0009	0.00288	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SCT—pancreatic cancer	0.000893	0.00286	CbGpPWpGaD
Maraviroc—CCR5—Disease—DTX4—pancreatic cancer	0.000869	0.00278	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRLHR—pancreatic cancer	0.000854	0.00273	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCK—pancreatic cancer	0.000852	0.00273	CbGpPWpGaD
Maraviroc—CCR5—Disease—PPP2R5B—pancreatic cancer	0.000846	0.00271	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CNR2—pancreatic cancer	0.000831	0.00266	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GLP1R—pancreatic cancer	0.000831	0.00266	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCKAR—pancreatic cancer	0.000817	0.00262	CbGpPWpGaD
Maraviroc—CCR5—Disease—HEY2—pancreatic cancer	0.000814	0.00261	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IAPP—pancreatic cancer	0.00081	0.00259	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.00081	0.00259	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ZNRF3—pancreatic cancer	0.000803	0.00257	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ACVR1B—pancreatic cancer	0.000803	0.00257	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000778	0.00249	CbGpPWpGaD
Maraviroc—CCR5—Disease—HEY1—pancreatic cancer	0.000754	0.00241	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SHH—pancreatic cancer	0.000745	0.00238	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IAPP—pancreatic cancer	0.000736	0.00235	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—DTX1—pancreatic cancer	0.000726	0.00232	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SSTR3—pancreatic cancer	0.000726	0.00232	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—SST—pancreatic cancer	0.000711	0.00228	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTHLH—pancreatic cancer	0.000706	0.00226	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTCH1—pancreatic cancer	0.000706	0.00226	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SSTR1—pancreatic cancer	0.000696	0.00223	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PPY—pancreatic cancer	0.000683	0.00219	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SSTR2—pancreatic cancer	0.00067	0.00215	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAG2—pancreatic cancer	0.000668	0.00214	CbGpPWpGaD
Maraviroc—CCR5—Disease—MEN1—pancreatic cancer	0.000659	0.00211	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CNR1—pancreatic cancer	0.000656	0.0021	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC2A2—pancreatic cancer	0.000654	0.00209	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCKBR—pancreatic cancer	0.000647	0.00207	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—SST—pancreatic cancer	0.000646	0.00207	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000644	0.00206	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GCG—pancreatic cancer	0.000634	0.00203	CbGpPWpGaD
Maraviroc—CCR5—Disease—SHH—pancreatic cancer	0.000628	0.00201	CbGpPWpGaD
Maraviroc—CCR5—Disease—IAPP—pancreatic cancer	0.000621	0.00199	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GLI1—pancreatic cancer	0.000609	0.00195	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—DTX4—pancreatic cancer	0.000609	0.00195	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000605	0.00194	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CNR1—pancreatic cancer	0.000596	0.00191	CbGpPWpGaD
Maraviroc—CCR5—Disease—HSPA1B—pancreatic cancer	0.000596	0.00191	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000592	0.0019	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRP1—pancreatic cancer	0.000592	0.0019	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GCG—pancreatic cancer	0.000576	0.00184	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HEY2—pancreatic cancer	0.00057	0.00182	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GAST—pancreatic cancer	0.000557	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGTR1—pancreatic cancer	0.000549	0.00176	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAG1—pancreatic cancer	0.000533	0.00171	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SCT—pancreatic cancer	0.000528	0.00169	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HEY1—pancreatic cancer	0.000528	0.00169	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD44—pancreatic cancer	0.000507	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCK—pancreatic cancer	0.000504	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Disease—HSPA1A—pancreatic cancer	0.000503	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CNR2—pancreatic cancer	0.000491	0.00157	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GLP1R—pancreatic cancer	0.000491	0.00157	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—pancreatic cancer	0.00049	0.00157	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCKAR—pancreatic cancer	0.000483	0.00155	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAG2—pancreatic cancer	0.000468	0.0015	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MEN1—pancreatic cancer	0.000461	0.00148	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SHH—pancreatic cancer	0.00044	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH4—pancreatic cancer	0.000437	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IAPP—pancreatic cancer	0.000435	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTHLH—pancreatic cancer	0.000417	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTCH1—pancreatic cancer	0.000417	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Disease—SMAD4—pancreatic cancer	0.0004	0.00128	CbGpPWpGaD
Maraviroc—CCR5—Disease—HES1—pancreatic cancer	0.000391	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SST—pancreatic cancer	0.000382	0.00122	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000376	0.0012	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAG1—pancreatic cancer	0.000373	0.0012	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH3—pancreatic cancer	0.000372	0.00119	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000372	0.00119	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CNR1—pancreatic cancer	0.000352	0.00113	CbGpPWpGaD
Maraviroc—Fatigue—Irinotecan—pancreatic cancer	0.000351	0.000654	CcSEcCtD
Maraviroc—Paraesthesia—Fluorouracil—pancreatic cancer	0.00035	0.000652	CcSEcCtD
Maraviroc—Alopecia—Docetaxel—pancreatic cancer	0.00035	0.000652	CcSEcCtD
Maraviroc—Pruritus—Sunitinib—pancreatic cancer	0.000349	0.000651	CcSEcCtD
Maraviroc—Breast disorder—Epirubicin—pancreatic cancer	0.000349	0.00065	CcSEcCtD
Maraviroc—Constipation—Irinotecan—pancreatic cancer	0.000348	0.000648	CcSEcCtD
Maraviroc—Pain—Irinotecan—pancreatic cancer	0.000348	0.000648	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000347	0.000648	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000347	0.000648	CcSEcCtD
Maraviroc—Mental disorder—Docetaxel—pancreatic cancer	0.000347	0.000646	CcSEcCtD
Maraviroc—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000345	0.000643	CcSEcCtD
Maraviroc—Malnutrition—Docetaxel—pancreatic cancer	0.000345	0.000642	CcSEcCtD
Maraviroc—Erythema—Docetaxel—pancreatic cancer	0.000345	0.000642	CcSEcCtD
Maraviroc—Decreased appetite—Gemcitabine—pancreatic cancer	0.000344	0.000642	CcSEcCtD
Maraviroc—Nausea—Tamoxifen—pancreatic cancer	0.000342	0.000638	CcSEcCtD
Maraviroc—CCR5—Disease—TERT—pancreatic cancer	0.000342	0.0011	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000342	0.000637	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000342	0.00109	CbGpPWpGaD
Maraviroc—Fatigue—Gemcitabine—pancreatic cancer	0.000342	0.000637	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.00034	0.000634	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GCG—pancreatic cancer	0.00034	0.00109	CbGpPWpGaD
Maraviroc—Constipation—Gemcitabine—pancreatic cancer	0.000339	0.000631	CcSEcCtD
Maraviroc—Pain—Gemcitabine—pancreatic cancer	0.000339	0.000631	CcSEcCtD
Maraviroc—Nausea—Erlotinib—pancreatic cancer	0.000339	0.000631	CcSEcCtD
Maraviroc—Decreased appetite—Fluorouracil—pancreatic cancer	0.000339	0.000631	CcSEcCtD
Maraviroc—Diarrhoea—Sunitinib—pancreatic cancer	0.000338	0.00063	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000336	0.000627	CcSEcCtD
Maraviroc—Abdominal distension—Epirubicin—pancreatic cancer	0.000336	0.000626	CcSEcCtD
Maraviroc—Influenza—Epirubicin—pancreatic cancer	0.000333	0.000622	CcSEcCtD
Maraviroc—Pain—Fluorouracil—pancreatic cancer	0.000333	0.000621	CcSEcCtD
Maraviroc—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000333	0.00062	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000331	0.00106	CbGpPWpGaD
Maraviroc—Eosinophilia—Epirubicin—pancreatic cancer	0.00033	0.000615	CcSEcCtD
Maraviroc—CCR5—Disease—HIF1A—pancreatic cancer	0.000327	0.00105	CbGpPWpGaD
Maraviroc—Pancreatitis—Epirubicin—pancreatic cancer	0.000327	0.000609	CcSEcCtD
Maraviroc—Dizziness—Sunitinib—pancreatic cancer	0.000327	0.000609	CcSEcCtD
Maraviroc—CCR5—Disease—TSC2—pancreatic cancer	0.000326	0.00104	CbGpPWpGaD
Maraviroc—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000326	0.000608	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000326	0.000608	CcSEcCtD
Maraviroc—Angina pectoris—Epirubicin—pancreatic cancer	0.000325	0.000605	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AGTR1—pancreatic cancer	0.000324	0.00104	CbGpPWpGaD
Maraviroc—Breast disorder—Doxorubicin—pancreatic cancer	0.000323	0.000601	CcSEcCtD
Maraviroc—Body temperature increased—Irinotecan—pancreatic cancer	0.000322	0.000599	CcSEcCtD
Maraviroc—Abdominal pain—Irinotecan—pancreatic cancer	0.000322	0.000599	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000322	0.000599	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000322	0.000599	CcSEcCtD
Maraviroc—Bronchitis—Epirubicin—pancreatic cancer	0.000321	0.000598	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STK11—pancreatic cancer	0.00032	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOE—pancreatic cancer	0.000319	0.00102	CbGpPWpGaD
Maraviroc—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000319	0.000595	CcSEcCtD
Maraviroc—Anaemia—Docetaxel—pancreatic cancer	0.000318	0.000593	CcSEcCtD
Maraviroc—Pancytopenia—Epirubicin—pancreatic cancer	0.000317	0.00059	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000315	0.000587	CcSEcCtD
Maraviroc—Vomiting—Sunitinib—pancreatic cancer	0.000314	0.000585	CcSEcCtD
Maraviroc—Body temperature increased—Gemcitabine—pancreatic cancer	0.000313	0.000584	CcSEcCtD
Maraviroc—Neutropenia—Epirubicin—pancreatic cancer	0.000312	0.000581	CcSEcCtD
Maraviroc—Rash—Sunitinib—pancreatic cancer	0.000311	0.00058	CcSEcCtD
Maraviroc—Dermatitis—Sunitinib—pancreatic cancer	0.000311	0.00058	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—pancreatic cancer	0.000311	0.000579	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.00031	0.000578	CcSEcCtD
Maraviroc—Headache—Sunitinib—pancreatic cancer	0.000309	0.000576	CcSEcCtD
Maraviroc—Syncope—Docetaxel—pancreatic cancer	0.000309	0.000576	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—pancreatic cancer	0.000309	0.000575	CcSEcCtD
Maraviroc—Leukopenia—Docetaxel—pancreatic cancer	0.000308	0.000575	CcSEcCtD
Maraviroc—Body temperature increased—Fluorouracil—pancreatic cancer	0.000308	0.000574	CcSEcCtD
Maraviroc—Eosinophilia—Doxorubicin—pancreatic cancer	0.000306	0.000569	CcSEcCtD
Maraviroc—Loss of consciousness—Docetaxel—pancreatic cancer	0.000303	0.000564	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—pancreatic cancer	0.000303	0.000564	CcSEcCtD
Maraviroc—Cough—Docetaxel—pancreatic cancer	0.000301	0.00056	CcSEcCtD
Maraviroc—Angina pectoris—Doxorubicin—pancreatic cancer	0.000301	0.00056	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—pancreatic cancer	0.0003	0.000962	CbGpPWpGaD
Maraviroc—Hypersensitivity—Irinotecan—pancreatic cancer	0.0003	0.000558	CcSEcCtD
Maraviroc—Pneumonia—Epirubicin—pancreatic cancer	0.000299	0.000557	CcSEcCtD
Maraviroc—Convulsion—Docetaxel—pancreatic cancer	0.000298	0.000556	CcSEcCtD
Maraviroc—Infestation—Epirubicin—pancreatic cancer	0.000297	0.000554	CcSEcCtD
Maraviroc—Infestation NOS—Epirubicin—pancreatic cancer	0.000297	0.000554	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—pancreatic cancer	0.000297	0.000553	CcSEcCtD
Maraviroc—CCR5—Disease—NOTCH1—pancreatic cancer	0.000295	0.000944	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000295	0.000549	CcSEcCtD
Maraviroc—Myalgia—Docetaxel—pancreatic cancer	0.000293	0.000547	CcSEcCtD
Maraviroc—Nausea—Sunitinib—pancreatic cancer	0.000293	0.000547	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—pancreatic cancer	0.000293	0.000546	CcSEcCtD
Maraviroc—Renal failure—Epirubicin—pancreatic cancer	0.000292	0.000545	CcSEcCtD
Maraviroc—Asthenia—Irinotecan—pancreatic cancer	0.000292	0.000544	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000291	0.000543	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000291	0.000543	CcSEcCtD
Maraviroc—Stomatitis—Epirubicin—pancreatic cancer	0.00029	0.00054	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—pancreatic cancer	0.00029	0.00054	CcSEcCtD
Maraviroc—Conjunctivitis—Epirubicin—pancreatic cancer	0.000289	0.000539	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—pancreatic cancer	0.000289	0.000538	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000288	0.000923	CbGpPWpGaD
Maraviroc—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000287	0.000535	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000287	0.000534	CcSEcCtD
Maraviroc—CCR5—Disease—EGF—pancreatic cancer	0.000285	0.000912	CbGpPWpGaD
Maraviroc—Asthenia—Gemcitabine—pancreatic cancer	0.000284	0.00053	CcSEcCtD
Maraviroc—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000281	0.000524	CcSEcCtD
Maraviroc—Oedema—Docetaxel—pancreatic cancer	0.000281	0.000524	CcSEcCtD
Maraviroc—Pruritus—Gemcitabine—pancreatic cancer	0.00028	0.000522	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SMAD4—pancreatic cancer	0.00028	0.000896	CbGpPWpGaD
Maraviroc—Infection—Docetaxel—pancreatic cancer	0.000279	0.000521	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—pancreatic cancer	0.000279	0.00052	CcSEcCtD
Maraviroc—Diarrhoea—Irinotecan—pancreatic cancer	0.000278	0.000519	CcSEcCtD
Maraviroc—Agranulocytosis—Epirubicin—pancreatic cancer	0.000277	0.000517	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000277	0.000887	CbGpPWpGaD
Maraviroc—Pneumonia—Doxorubicin—pancreatic cancer	0.000277	0.000516	CcSEcCtD
Maraviroc—Shock—Docetaxel—pancreatic cancer	0.000277	0.000516	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—pancreatic cancer	0.000276	0.000514	CcSEcCtD
Maraviroc—Pruritus—Fluorouracil—pancreatic cancer	0.000276	0.000514	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—pancreatic cancer	0.000275	0.000513	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—pancreatic cancer	0.000275	0.000513	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HES1—pancreatic cancer	0.000273	0.000875	CbGpPWpGaD
Maraviroc—Skin disorder—Docetaxel—pancreatic cancer	0.000273	0.000509	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000273	0.000508	CcSEcCtD
Maraviroc—Diarrhoea—Gemcitabine—pancreatic cancer	0.000271	0.000505	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—pancreatic cancer	0.00027	0.000504	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.00027	0.000503	CcSEcCtD
Maraviroc—Dizziness—Irinotecan—pancreatic cancer	0.000269	0.000501	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—pancreatic cancer	0.000268	0.0005	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—pancreatic cancer	0.000268	0.0005	CcSEcCtD
Maraviroc—Anorexia—Docetaxel—pancreatic cancer	0.000268	0.000499	CcSEcCtD
Maraviroc—Rhinitis—Epirubicin—pancreatic cancer	0.000268	0.000499	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000267	0.000498	CcSEcCtD
Maraviroc—Diarrhoea—Fluorouracil—pancreatic cancer	0.000267	0.000497	CcSEcCtD
Maraviroc—Pharyngitis—Epirubicin—pancreatic cancer	0.000265	0.000494	CcSEcCtD
Maraviroc—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000264	0.000491	CcSEcCtD
Maraviroc—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000262	0.000489	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000262	0.000838	CbGpPWpGaD
Maraviroc—Urethral disorder—Epirubicin—pancreatic cancer	0.000262	0.000488	CcSEcCtD
Maraviroc—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00026	0.000485	CcSEcCtD
Maraviroc—Vomiting—Irinotecan—pancreatic cancer	0.000259	0.000482	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—pancreatic cancer	0.000258	0.000481	CcSEcCtD
Maraviroc—Dizziness—Fluorouracil—pancreatic cancer	0.000258	0.00048	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000257	0.000478	CcSEcCtD
Maraviroc—Rash—Irinotecan—pancreatic cancer	0.000256	0.000478	CcSEcCtD
Maraviroc—Dermatitis—Irinotecan—pancreatic cancer	0.000256	0.000477	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000256	0.000477	CcSEcCtD
Maraviroc—Headache—Irinotecan—pancreatic cancer	0.000255	0.000475	CcSEcCtD
Maraviroc—Insomnia—Docetaxel—pancreatic cancer	0.000254	0.000474	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CD—pancreatic cancer	0.000253	0.000811	CbGpPWpGaD
Maraviroc—Paraesthesia—Docetaxel—pancreatic cancer	0.000252	0.000471	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—pancreatic cancer	0.000252	0.00047	CcSEcCtD
Maraviroc—Vomiting—Gemcitabine—pancreatic cancer	0.000252	0.000469	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—pancreatic cancer	0.000252	0.000805	CbGpPWpGaD
Maraviroc—Rash—Gemcitabine—pancreatic cancer	0.00025	0.000466	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—pancreatic cancer	0.00025	0.000465	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—pancreatic cancer	0.000249	0.000465	CcSEcCtD
Maraviroc—Headache—Gemcitabine—pancreatic cancer	0.000248	0.000463	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—pancreatic cancer	0.000248	0.000462	CcSEcCtD
Maraviroc—Vomiting—Fluorouracil—pancreatic cancer	0.000248	0.000462	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—pancreatic cancer	0.000248	0.000461	CcSEcCtD
Maraviroc—Rash—Fluorouracil—pancreatic cancer	0.000246	0.000458	CcSEcCtD
Maraviroc—Dermatitis—Fluorouracil—pancreatic cancer	0.000245	0.000457	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—pancreatic cancer	0.000245	0.000457	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—pancreatic cancer	0.000244	0.000456	CcSEcCtD
Maraviroc—Headache—Fluorouracil—pancreatic cancer	0.000244	0.000455	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000244	0.000455	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000243	0.000452	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000243	0.000452	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—pancreatic cancer	0.000242	0.000452	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—pancreatic cancer	0.000242	0.000451	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—pancreatic cancer	0.000242	0.000451	CcSEcCtD
Maraviroc—Nausea—Irinotecan—pancreatic cancer	0.000242	0.00045	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000241	0.000448	CcSEcCtD
Maraviroc—Pain—Docetaxel—pancreatic cancer	0.00024	0.000448	CcSEcCtD
Maraviroc—Constipation—Docetaxel—pancreatic cancer	0.00024	0.000448	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TERT—pancreatic cancer	0.00024	0.000767	CbGpPWpGaD
Maraviroc—Alopecia—Epirubicin—pancreatic cancer	0.000236	0.00044	CcSEcCtD
Maraviroc—Nausea—Gemcitabine—pancreatic cancer	0.000235	0.000439	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—pancreatic cancer	0.000234	0.000436	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000234	0.000435	CcSEcCtD
Maraviroc—Erythema—Epirubicin—pancreatic cancer	0.000232	0.000433	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—pancreatic cancer	0.000232	0.000433	CcSEcCtD
Maraviroc—Nausea—Fluorouracil—pancreatic cancer	0.000231	0.000431	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—pancreatic cancer	0.000231	0.00043	CcSEcCtD
Maraviroc—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00023	0.000428	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000229	0.000427	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HIF1A—pancreatic cancer	0.000229	0.000733	CbGpPWpGaD
Maraviroc—Flatulence—Epirubicin—pancreatic cancer	0.000229	0.000427	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TSC2—pancreatic cancer	0.000229	0.000732	CbGpPWpGaD
Maraviroc—Angiopathy—Doxorubicin—pancreatic cancer	0.000224	0.000418	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOE—pancreatic cancer	0.000224	0.000716	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000223	0.000415	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—pancreatic cancer	0.000222	0.000414	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—pancreatic cancer	0.000222	0.000414	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CB—pancreatic cancer	0.000221	0.000707	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KDR—pancreatic cancer	0.000219	0.000701	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—pancreatic cancer	0.000219	0.000701	CbGpPWpGaD
Maraviroc—Alopecia—Doxorubicin—pancreatic cancer	0.000218	0.000407	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—pancreatic cancer	0.000216	0.000403	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—pancreatic cancer	0.000215	0.000401	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—pancreatic cancer	0.000215	0.000401	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—pancreatic cancer	0.000215	0.0004	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—pancreatic cancer	0.000212	0.000395	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NFKBIA—pancreatic cancer	0.000208	0.000667	CbGpPWpGaD
Maraviroc—Syncope—Epirubicin—pancreatic cancer	0.000208	0.000388	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—pancreatic cancer	0.000208	0.000388	CcSEcCtD
Maraviroc—Hypersensitivity—Docetaxel—pancreatic cancer	0.000207	0.000386	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—pancreatic cancer	0.000206	0.000661	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—pancreatic cancer	0.000204	0.000381	CcSEcCtD
Maraviroc—Cough—Epirubicin—pancreatic cancer	0.000203	0.000378	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—pancreatic cancer	0.000202	0.000646	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—NRAS—pancreatic cancer	0.000202	0.000646	CbGpPWpGaD
Maraviroc—Asthenia—Docetaxel—pancreatic cancer	0.000202	0.000376	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—pancreatic cancer	0.000201	0.000375	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGF—pancreatic cancer	0.0002	0.000639	CbGpPWpGaD
Maraviroc—Pruritus—Docetaxel—pancreatic cancer	0.000199	0.000371	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—pancreatic cancer	0.000199	0.00037	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—pancreatic cancer	0.000198	0.000369	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—pancreatic cancer	0.000197	0.000367	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000196	0.000366	CcSEcCtD
Maraviroc—CCR5—Disease—CTNNB1—pancreatic cancer	0.000196	0.000627	CbGpPWpGaD
Maraviroc—Discomfort—Epirubicin—pancreatic cancer	0.000195	0.000364	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—pancreatic cancer	0.000193	0.000359	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—pancreatic cancer	0.000192	0.000359	CcSEcCtD
Maraviroc—Diarrhoea—Docetaxel—pancreatic cancer	0.000192	0.000359	CcSEcCtD
Maraviroc—CCR5—Disease—PTEN—pancreatic cancer	0.000191	0.000611	CbGpPWpGaD
Maraviroc—Oedema—Epirubicin—pancreatic cancer	0.00019	0.000353	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000189	0.000352	CcSEcCtD
Maraviroc—Infection—Epirubicin—pancreatic cancer	0.000188	0.000351	CcSEcCtD
Maraviroc—Cough—Doxorubicin—pancreatic cancer	0.000188	0.00035	CcSEcCtD
Maraviroc—Shock—Epirubicin—pancreatic cancer	0.000187	0.000348	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—pancreatic cancer	0.000186	0.000347	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—pancreatic cancer	0.000186	0.000347	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—pancreatic cancer	0.000186	0.000347	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—pancreatic cancer	0.000184	0.000343	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EGFR—pancreatic cancer	0.000184	0.000589	CbGpPWpGaD
Maraviroc—Myalgia—Doxorubicin—pancreatic cancer	0.000183	0.000341	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—pancreatic cancer	0.000182	0.00034	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000182	0.000339	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—pancreatic cancer	0.000181	0.000337	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—pancreatic cancer	0.000181	0.000337	CcSEcCtD
Maraviroc—Vomiting—Docetaxel—pancreatic cancer	0.000179	0.000333	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—pancreatic cancer	0.000177	0.000568	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—pancreatic cancer	0.000177	0.00033	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—pancreatic cancer	0.000177	0.00033	CcSEcCtD
Maraviroc—CCR5—Disease—SRC—pancreatic cancer	0.000177	0.000567	CbGpPWpGaD
Maraviroc—Headache—Docetaxel—pancreatic cancer	0.000176	0.000328	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000176	0.000563	CbGpPWpGaD
Maraviroc—Oedema—Doxorubicin—pancreatic cancer	0.000175	0.000327	CcSEcCtD
Maraviroc—Infection—Doxorubicin—pancreatic cancer	0.000174	0.000325	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KRAS—pancreatic cancer	0.000174	0.000556	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000173	0.000322	CcSEcCtD
Maraviroc—Shock—Doxorubicin—pancreatic cancer	0.000173	0.000322	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000172	0.000321	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—pancreatic cancer	0.000172	0.00032	CcSEcCtD
Maraviroc—CCR5—Disease—STAT3—pancreatic cancer	0.000171	0.000546	CbGpPWpGaD
Maraviroc—Skin disorder—Doxorubicin—pancreatic cancer	0.00017	0.000318	CcSEcCtD
Maraviroc—CCR5—Disease—NRAS—pancreatic cancer	0.00017	0.000545	CbGpPWpGaD
Maraviroc—Paraesthesia—Epirubicin—pancreatic cancer	0.00017	0.000317	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—pancreatic cancer	0.000167	0.000312	CcSEcCtD
Maraviroc—Nausea—Docetaxel—pancreatic cancer	0.000167	0.000311	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—pancreatic cancer	0.000165	0.000307	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000164	0.000305	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—pancreatic cancer	0.000164	0.000305	CcSEcCtD
Maraviroc—Constipation—Epirubicin—pancreatic cancer	0.000162	0.000302	CcSEcCtD
Maraviroc—Pain—Epirubicin—pancreatic cancer	0.000162	0.000302	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00016	0.000298	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—pancreatic cancer	0.00016	0.000511	CbGpPWpGaD
Maraviroc—Insomnia—Doxorubicin—pancreatic cancer	0.000159	0.000296	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—pancreatic cancer	0.000159	0.000508	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—pancreatic cancer	0.000158	0.000507	CbGpPWpGaD
Maraviroc—Paraesthesia—Doxorubicin—pancreatic cancer	0.000158	0.000294	CcSEcCtD
Maraviroc—CCR5—Disease—EGFR—pancreatic cancer	0.000155	0.000497	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000155	0.000289	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—pancreatic cancer	0.000155	0.000495	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—pancreatic cancer	0.000153	0.000284	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000151	0.000282	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—pancreatic cancer	0.000151	0.000282	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—pancreatic cancer	0.00015	0.00028	CcSEcCtD
Maraviroc—Pain—Doxorubicin—pancreatic cancer	0.00015	0.00028	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—pancreatic cancer	0.00015	0.000279	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—pancreatic cancer	0.00015	0.000279	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL8—pancreatic cancer	0.000149	0.000476	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—pancreatic cancer	0.000148	0.000473	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—pancreatic cancer	0.000147	0.000469	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—pancreatic cancer	0.000144	0.00046	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000143	0.000267	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CASP3—pancreatic cancer	0.000142	0.000455	CbGpPWpGaD
Maraviroc—Hypersensitivity—Epirubicin—pancreatic cancer	0.00014	0.00026	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—pancreatic cancer	0.000139	0.000259	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—pancreatic cancer	0.000139	0.000259	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCND1—pancreatic cancer	0.000139	0.000443	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—pancreatic cancer	0.000137	0.000439	CbGpPWpGaD
Maraviroc—Asthenia—Epirubicin—pancreatic cancer	0.000136	0.000254	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CA—pancreatic cancer	0.000135	0.000431	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—pancreatic cancer	0.000134	0.00043	CbGpPWpGaD
Maraviroc—Pruritus—Epirubicin—pancreatic cancer	0.000134	0.00025	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTEN—pancreatic cancer	0.000134	0.000428	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—pancreatic cancer	0.00013	0.000417	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—pancreatic cancer	0.00013	0.000242	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000129	0.000241	CcSEcCtD
Maraviroc—Asthenia—Doxorubicin—pancreatic cancer	0.000126	0.000235	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—pancreatic cancer	0.000125	0.000234	CcSEcCtD
Maraviroc—CCR5—Disease—HRAS—pancreatic cancer	0.000125	0.000399	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—pancreatic cancer	0.000124	0.000231	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SRC—pancreatic cancer	0.000124	0.000397	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—pancreatic cancer	0.000121	0.000386	CbGpPWpGaD
Maraviroc—Vomiting—Epirubicin—pancreatic cancer	0.000121	0.000225	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—pancreatic cancer	0.00012	0.000224	CcSEcCtD
Maraviroc—Rash—Epirubicin—pancreatic cancer	0.00012	0.000223	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STAT3—pancreatic cancer	0.00012	0.000383	CbGpPWpGaD
Maraviroc—Dermatitis—Epirubicin—pancreatic cancer	0.000119	0.000223	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NRAS—pancreatic cancer	0.000119	0.000382	CbGpPWpGaD
Maraviroc—Headache—Epirubicin—pancreatic cancer	0.000119	0.000221	CcSEcCtD
Maraviroc—Dizziness—Doxorubicin—pancreatic cancer	0.000116	0.000216	CcSEcCtD
Maraviroc—Nausea—Epirubicin—pancreatic cancer	0.000113	0.00021	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—pancreatic cancer	0.000112	0.000208	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—pancreatic cancer	0.000111	0.000356	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—pancreatic cancer	0.000111	0.000355	CbGpPWpGaD
Maraviroc—Rash—Doxorubicin—pancreatic cancer	0.000111	0.000206	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—pancreatic cancer	0.000111	0.000206	CcSEcCtD
Maraviroc—CCR5—Disease—AKT1—pancreatic cancer	0.00011	0.000352	CbGpPWpGaD
Maraviroc—Headache—Doxorubicin—pancreatic cancer	0.00011	0.000205	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGFR—pancreatic cancer	0.000109	0.000348	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—pancreatic cancer	0.000104	0.000194	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—pancreatic cancer	0.000103	0.000329	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—pancreatic cancer	9.43e-05	0.000302	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—pancreatic cancer	9.12e-05	0.000292	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—pancreatic cancer	8.73e-05	0.000279	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—pancreatic cancer	7.7e-05	0.000247	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PRSS1—pancreatic cancer	7.16e-05	0.000229	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ARG2—pancreatic cancer	6.21e-05	0.000199	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMP—pancreatic cancer	5.43e-05	0.000174	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.37e-05	0.00014	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DPYD—pancreatic cancer	4.3e-05	0.000138	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	4.08e-05	0.000131	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD44—pancreatic cancer	3.16e-05	0.000101	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCG—pancreatic cancer	3.03e-05	9.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—STK11—pancreatic cancer	2.85e-05	9.12e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.45e-05	7.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOE—pancreatic cancer	1.99e-05	6.38e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.8e-05	5.76e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.74e-05	5.56e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.58e-05	5.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.38e-05	4.41e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.37e-05	4.37e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.19e-05	3.81e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	8.41e-06	2.69e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—pancreatic cancer	6.87e-06	2.2e-05	CbGpPWpGaD
